Figure 2.

Tpl2 inhibitor reduced tumor angiogenesis and prevented angiogenic factor-induced proliferation of HUVECs. (A) Immunohistochemistry of tumors stained with anti-CD31. Right panel: Quantitation of tumor vasculature indicated that Tpl2 inhibitor prevented angiogenesis. The MVD of CD31 in each section was measured in five images from each treatment (n = 5). Bars, MVD in each treatment; original magnification, x100. (B) HUVECs were preincubated with Tpl2 inhibitor or (C) transfected with Tpl2 siRNA or scrambled Tpl2 siRNA, followed by stimulation with VEGF, bFGF, or CXCL1. Cell viability was determined by MTS assay. All data are presented as means ± SEM of five independent experiments. *P < .05 compared to controls.